Last reviewed · How we verify

Methylprednisolone or equivalent

Sanofi · FDA-approved active Small molecule

Methylprednisolone or equivalent is a Glucocorticoid (corticosteroid) Small molecule drug developed by Sanofi. It is currently FDA-approved for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.

Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Polymyalgia rheumatica.

At a glance

Generic nameMethylprednisolone or equivalent
SponsorSanofi
Drug classGlucocorticoid (corticosteroid)
TargetGlucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaImmunology, Rheumatology, Endocrinology
PhaseFDA-approved

Mechanism of action

Methylprednisolone acts as a potent immunosuppressant and anti-inflammatory agent by binding intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and proliferation. It is commonly used as a reference standard for corticosteroid potency comparisons.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methylprednisolone or equivalent

What is Methylprednisolone or equivalent?

Methylprednisolone or equivalent is a Glucocorticoid (corticosteroid) drug developed by Sanofi, indicated for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.

How does Methylprednisolone or equivalent work?

Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

What is Methylprednisolone or equivalent used for?

Methylprednisolone or equivalent is indicated for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency, Cerebral edema, Multiple sclerosis relapse.

Who makes Methylprednisolone or equivalent?

Methylprednisolone or equivalent is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is Methylprednisolone or equivalent in?

Methylprednisolone or equivalent belongs to the Glucocorticoid (corticosteroid) class. See all Glucocorticoid (corticosteroid) drugs at /class/glucocorticoid-corticosteroid.

What development phase is Methylprednisolone or equivalent in?

Methylprednisolone or equivalent is FDA-approved (marketed).

What are the side effects of Methylprednisolone or equivalent?

Common side effects of Methylprednisolone or equivalent include Hyperglycemia, Hypertension, Insomnia and mood changes, Increased infection risk, Osteoporosis (with chronic use), Gastrointestinal upset.

What does Methylprednisolone or equivalent target?

Methylprednisolone or equivalent targets Glucocorticoid receptor (GR) and is a Glucocorticoid (corticosteroid).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing